Your session is about to expire
← Back to Search
Methylene Blue for Dental Implants
Study Summary
This trial will compare the effects of two different treatments for implant surfaces with plaque-induced inflammation. One treatment will use mechanical debridement with adjunctive antimicrobial photodynamic therapy, and the other will just use mechanical debridement.
- Dental Implants
- Laser
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there still openings for individuals to participate in this research?
"Affirmative. Clinicaltrials.gov indicates that the trial, initially posted on February 14th 2020, is actively seeking patients to fill 64 available spots at 1 location."
What potential hazards are associated with Methylene Blue consumption?
"Due to its Phase 4 designation, which means FDA approval, Methylene Blue was rated a 3 for safety on our scale at Power."
What is the total size of the cohort involved in this research trial?
"Affirmative, per the information provided by clinicaltrials.gov this research is actively recruiting participants. This study was initially posted on February 14th 2020 and its latest update has been recorded on October 31st 2022. Sixty-four individuals can be enrolled at a single trial location."
What conditions typically warrant Methylene Blue as a course of treatment?
"Methylene Blue is known as an effective remedy for urethritis, nephritis, and inflammation."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Most responsive sites:
- University of Texas Health Science Center at Houston School of Dentistry: < 24 hours
Average response time
- < 1 Day
Share this study with friends
Copy Link
Messenger